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Numerous studies have recently examined the role of pentraxin 3 (PTX3) in clinical situations. The pentraxin family includes C-
reactiveprotein(CRP);however,unlikeCRP,PTX3isexpressedpredominantlyinatheroscleroticlesionsthatinvolvemacrophages,
neutrophils, dendritic cells, or smooth muscle cells. Interestingly, PTX3 gene expression in human endothelial cells is suppressed
to a greater extent by pitavastatin than the expression of 6,000 other human genes that have been examined, suggesting that PTX3
may be a novel biomarker for inﬂammatory cardiovascular disease. The expression and involvement of PTX3 in cardiovascular
diseases are discussed in this paper, along with the characteristics of PTX3 that make it a suitable biomarker; namely, that the
physiological concentration is known and it is independent of other risk factors. The results discussed in this paper suggest that
further investigations into the potential novel use of PTX3 as a biomarker for inﬂammatory cardiovascular disease should be
undertaken.
1.Introduction
Biomarkers are measurable and quantiﬁable biological
parameters that can have an important impact on clinical
situations. Ideal biomarkers are those that are associated
with disease clinical endpoints in observational studies
and clinical trials, and in some cases, they may even be
used as surrogate endpoints. Biomarkers must also be both
independent of established risk factors and recognized to
be a factor in the disease for which they are a marker. The
normal physiological expression of a potential biomarker
must also be known in order to interpret results, as well as
to generalize results to various population groups. Finally,
potential biomarkers must also have the ability to improve
overall prediction beyond that of traditional risk factors,
while assays to detect them must have an acceptable cost
and be subject to standardization in order to control for the
variability of measurements [1].
Basic research over the past decades has identiﬁed
numerous candidate genes and proteins as biomarkers for
cardiovascular disease. In the cardiovascular ﬁeld, such
biomarkers are useful not only for diagnosis but also as
indicators of disease trait (risk factor or risk marker), disease
state (preclinical or clinical), or disease rate (progression
or prognosis) [2]. One protein that has the potential to
be a viable biomarker for inﬂammatory vascular disease is
pentraxin 3 (PTX3).
2.Pentraxin3
PTX3 is an evolutionarily conserved, multimeric acute
phase inﬂammatory glycoprotein in the same family as the
well-establishedcardiovascularbiomarkerC-reactiveprotein
(CRP) [3, 4]. PTX3 also shares 98% identity with tumor
necrosis factor- (TNF-) stimulated gene 14 (TSG14) [5, 6].
PTX3 has been successfully identiﬁed by Breviario et al.
using diﬀerential screening of a cDNA library from human
umbilical vein endothelial cells (HUVECs) stimulated by
interleukin-1 beta [5], as well as by Gustin et al. using the
2D-DIGE approach to detect PTX3 in HUVECs stimulated
by lysophospholipids [7]. Our group also identiﬁed PTX3
whenwewereinvestigatingstatinasatargetgeneinHUVECs2 International Journal of Vascular Medicine
incubated with pitavastatin for 24 hours prior to RNA
extraction [8]. Interestingly, chip analysis has demonstrated
that,ofthe6,000humangenesthathavebeeninvestigatedfor
response to pitavastatin treatment, PTX3 gene expression is
suppressed in human endothelial cells to the greatest extent.
PTX3 synthesis is stimulated in endothelial cells,
macrophages, myeloid cells, and dendritic cells by cytokines
and endotoxins such as bacterial products, interleukin-1,
and TNF [9–11]. The role of PTX3 in neutrophils has also
been gradually elucidated by a number of studies. Once
synthesized, PTX3 is predominantly organized into covalent
octamers through disulﬁde bonds [12]. Although PTX3
is mainly localized in lactoferrin positive-speciﬁc granules
[13, 14], it is translocated to the surface of late apoptotic
neutrophils upon stimulation, where it accumulates in blebs
and is rapidly released. PTX3 then binds with the high-
aﬃnity complement component C1q to initiate the classical
pathway of complement activation and facilitate pathogen
recognition by macrophages.
3. Suitabilityof PTX3 as a Biomarker
3.1. PTX3 Expression in Cardiovascular Diseases
3.1.1. Acute Coronary Syndrome (ACS). The expression of
PTX3 has been found to be increased in patients with
acute myocardial infarction (AMI). For instance, Peri et
al. observed that patients (n = 37) with AMI who were
admitted to the coronary care unit within 3.2 ± 3.2h o u r s
of the onset of symptoms had increased plasma PTX3 over
time [15]. In this study, plasma PTX3 levels were found to
peak at a median of 7.5 hours after AMI, and to return
to normal levels after 3 days. Similarly, in murine models
of AMI, PTX3 mRNA is expressed within 4 hours of the
ligation of the coronary artery, reaches peak levels after 24
hours, and returns to normal levels 3 days later [16]. We have
also found that plasma PTX3 levels are increased in patients
(n = 16) with unstable angina pectoris (UAP; 6.20ng/mL)
[17]. Such ﬁndings have led to the investigation of PTX3
expression levels as a potential prognostic indicator of
disease. Matsui et al. found that the expression of more than
3.1ng/mL of PTX3 in patients with UAP/non-ST-elevation
MI (n = 204) was predictive of the occurrence of a 6-month
cardiac event, including cardiac death, rehospitalization for
ACS, and rehospitalization for worsening heart failure [18],
while Latini et al. have shown that the expression of more
than 10.73ng/mL of PTX3 predicted 3-month mortality in
patients with AMI (n = 724) [19].
3.1.2. Congestive Heart Failure. PTX3 has also been impli-
cated as a predictor of adverse clinical outcomes in patients
with heart failure (n = 196) in a study with a median
follow-up period of 655 days and an ejection fraction of less
than 50% [20]. In a further study by Matsubara et al. that
focused on patients with heart failure with normal ejection
fraction (HFNEF), plasma PTX3 levels were also found to be
increased (3.26 (2.36–4.35)ng/mL). This was observed even
in patients with HFNEF, although B-type natriuretic peptide
(BNP) was within normal limits [21].
3.1.3. Sleep Apnea Syndrome. Plasma PTX3 levels have also
been suggested to be a good marker for the response to
treatment of patients with obstructive sloop apnea (OSA).
Kasai et al. demonstrated that not only did patients with
OSA (n = 50) express higher levels of plasma PTX3 than
individuals in an age- and body mass index-matched control
group, but also that continuous positive airway pressure
(CPAP) therapy led to a signiﬁcant reduction in plasma
PTX3 levels. While high sensitive CRP has previously been
suggested to be a highly sensitive candidate biomarker that
canreﬂectthestatusofpatientswithOSA,theﬁndingsofthis
study led the authors to conclude that plasma PTX3 levels
seem to be a more suitable biomarker to monitor treatment
eﬀects in patients with OSA [22].
3.1.4. Heart Valvular Disease. In a study by Naito et al. that
investigated PTX3 expression patterns in patients with aortic
valve stenosis (AS) or regurgitation (AR), it was found that
the expression of plasma PTX3 was signiﬁcantly increased
in patients with AS. Furthermore, PTX3 was found to be
expressed predominantly in macrophage cells in the aortic
valves of these patients [23].
3.2. PTX3 Involvement in Cardiovascular Diseases. Several
studies have examined why plasma PTX3 levels are increased
in patients with cardiovascular disease, and those that have
targeted the PTX3 gene in mice suggest that plasma PTX3
levels may increase in order to confer protection against
cardiac tissue damage [16, 24]. For instance, in a model
of AMI caused by coronary artery ligation, PTX3-knockout
mice showed exacerbated heart damage with a greater no-
reﬂow area and increased inﬂammatory response, including
increased neutrophil inﬁltration, a decreased number of
capillaries, and an increased number of apoptotic cardiomy-
ocytes [16]. This phenotype was reversed by the expression
of exogenous PTX3.
PTX3 expression has also been examined using dou-
ble knockout mice in which PTX3 and apolipoprotein E
have been targeted. When gene expression in the aortic
arches of these mice was analyzed using gene chip, it
was found that several transcription factors involved in
intracellular proinﬂammatory signaling, such as nuclear
factor-kappa B and the related proteins Irak1, Fos, Jun,
GATA3, GATA4, Egr2, and Egr3, were upregulated after the
mice had been fed an atherogenic diet for 16 weeks. The
mRNA expression levels of intracellular adhesion molecule,
vascular cell adhesion molecule-1, endothelial leukocyte
adhesion molecule-1, and platelet/endothelial cell adhesion
molecule were also found to be increased in the vascular
wall of double knockout mice when compared to those
of wild-type mice [24]. Furthermore, the lack of PTX3 in
a proatherogenic background may be associated with an
increased inﬂammatory status in the vascular wall, which in
turn contributes to the atherogenic process. In contrast, the
transgenic overexpression of PTX3 has been found to result
in greater resistance to lipopolysaccharide toxicity and cecal
ligation and puncture [26]. There is also evidence that PTX3
may modulate inﬂammation-associated tissue damage.International Journal of Vascular Medicine 3
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Figure 1: Geometric mean PTX3 plasma levels in men and women [25]. (a) Mean and conﬁdence interval of natural log transformed PTX3
in men and women. Plasma PTX3 levels in men are signiﬁcant lower than those in women (men, 1.87 (1.81, 1.94)ng/mL; women, 2.12
(2.05, 2.19)ng/mL). ∗P<0.0001. (b) Plasma PTX3 levels according to quartiles of age in men. Quartile 1 (Q1): 37–49 years old; 1.62 (1.50,
1.74)ng/mL. Quartile 2 (Q2): 50–57 years old; 1.82 (1.70, 1.94) ng/mL. Quartile 3 (Q3): 58–68 years old; 1.98 (1.86, 2.11) ng/mL. Quartile
4 (Q4): 69–87 years old; 2.14 (2.02, 2.27)ng/mL. ∗P<0.001, Q1 versus Q3 and Q4; ∗∗P<0.0006, Q1 and Q2 versus Q4. (c) Plasma PTX3
levels according to quartiles of age in women. Quartile 1 (Q1): 38–52 years old; 2.05 (1.92, 2.18)ng/mL. Quartile 2 (Q2): 53–61 years old;
1.99 (1.87, 2.12)ng/mL. Quartile 3 (Q3): 62–70 years old; 2.10 (1.98, 2.23)ng/mL. Quartile 4 (Q4): 71–85 years old; 2.23 (2.02, 2.46)ng/mL.
∗P<0.05, ∗∗P<0.01.
PTX3 has also been found to oﬀer protection against
atherosclerosis. As a relationship between PTX3 and the
cell adhesion molecule P-selectin in atherosclerotic lesions
has recently been reported, it is possible that PTX3 may
exert some of these eﬀects through an association with this
protein [27]. For instance, neutrophils rolling on P-selectin
in venules at the sites of infection or injury receive signals
that cause the release of PTX3 from speciﬁc granules. This
released PTX3 then selectively binds locally expressed P-
selectin, but not E- or L-selectin, in a paracrine manner,
while the dissociation of this complex is slowed by the
increased binding avidity due to the multimeric nature of
PTX3. As more neutrophils roll, they release more PTX3,
whichthenbindsmoreP-selectinmolecules.Thisconstitutes
a local negative feedback system that diminishes neutrophil
tethering, accelerates rolling, and enhances detachment.
Indeed, PTX3 expression has been found to decrease the
number of neutrophils rolling on P-selectin in vitro in
a concentration-dependent manner, while the injection of
PTX3 in vivo has been shown to reduce the number of neu-
trophils rolling in thrombin-stimulated mesenteric venules
of mice because PTX3 competitively inhibited between P-
selectin and P-selectin glycoprotein 1 (PSGL-1) bonds.
The source of anti-inﬂammatory PTX3 has also been
examined. By transplanting wild-type or PTX3-deﬁcient
bone marrow into irradiated wild-type or PTX3-deﬁcient
recipient mice, Deban et al. showed that PTX3 from hema-
topoietic cells is required to suppress neutrophil recruitment
into the pleural cavity in the ﬁrst 2 hours after chemokine
challenge. In this short time frame, neutrophils are the likely
source of PTX3, as they are the only hematopoietic cells that
store PTX3 [28].
Very recently, Maugeri et al. have reported data that
supports the release of PTX3 from activated neutrophils by
platelets in patients with ACS [28]. In this study, the total
amount of PTX3 in the neutrophils of patients with early4 International Journal of Vascular Medicine
AMI (early onset; <6hr),lateAMI(<48hr), stable coronary
artery disease, and healthy volunteers was measured using
FACS. As found in our study, the maximum plasma level of
PTX3 was reached at 6 hours after onset. Interestingly, the
lowest PTX3 levels were found in the neutrophils of patients
with early AMI, whereby confocal microscopy detected very
low PTX3 expression in neutrophils from patients with early
AMI and much higher PTX3 expression in neutrophils from
patients with late AMI. Furthermore, released PTX3 from
patients with early AMI was found to aggregate platelets
expressing P-selectin compare with late AMI [28]. From
these ﬁndings, PTX3 works as a cardioprotective to bind to
activated circulating platelets and reduce the inﬂammation
status in cardiovascular bed.
It has also been shown that plasma PTX3 levels increase
signiﬁcantly during widespread inﬂammations, such as sep-
sis [29]. In such scenarios, activated endothelial cells, den-
dritic cells, and/or macrophages may be major sources of
PTX3, and although it has recently been demonstrated that
PTX3 inhibits P-selectin-dependent adhesion [27], other,
still undeﬁned, mechanisms may also contribute to its anti-
inﬂammatory properties in vivo.
3.3. Physiological PTX3 Levels. The normal physiological
concentration of plasma PTX3 expression has been deter-
mined tobe approximately 2ng/mL ina studythatexamined
PTX3 levels in 1749 subjects (818 men and 931 women)
[25]. Interestingly, plasma PTX3 levels were found to be
signiﬁcantly lower in men than in women (1.87 (1.81,
1.94)ng/mL versus 2.12 (2.05, 2.19)ng/mL, P<0.0001)
(Figure 1(a)). They were also found to be signiﬁcantly higher
in the oldest age group in both men and women (lowest
quartile 1.62 (1.50, 1.74)ng/mL versus highest quartile 2.14
(2.02, 2.27) ng/mL in men, P<0.001; lowest quartile
2.05 (1.92, 2.18) ng/mL versus highest quartile 2.23 (2.02,
2.46)ng/mL in women, P<0.05; Figures 1(b) and 1(c)).
PTX3 levels were also inversely correlated with triglyceride
levels (r =− 0.19 in men and r =− 0.18 in women, P<
0.00001), and body mass index (r =− 0.16 in men and r =
−0.24 in women, P<0.00001).
3.4. PTX3 Independence from Established Risk Factors.
Plasma PTX3 levels have also been shown to be independent
of other coronary risk factors, including total cholesterol,
high-density lipoprotein (HDL) cholesterol, hemoglobin
A1C, smoking status, gender, and obesity (Table 1)[ 17].
Although Yamashina et al. have reported a brachial-ankle
pulse wave velocity (ba PWV) cutoﬀ value of 14.0m/s
for screening subjects at risk of developing cardiovascular
diseases in the general population [30], plasma PTX3 levels
are not diﬀerent between patients with ba PWV values of
more or less than 14.0m/s, or an intimal thickness of the
carotid artery of more or less than 1.0mm, which means
within normal limits [17].
4.PTX3 inOther Diseases
The human PTX3 proximal promoters contain AP-1, NF-
kappa B, Sp-1, and NF-IL6 binding sites [5]. Consequently,
Table 1: Geometric mean PTX3 plasma levels by CHD risk factors
[17].
Risk factor PTX3 (ng/mL; 95% CI) P value
TCHO 220mg/dL 2.16 (1.85–2.46) 0.51
<220mg/dL 2.30 (2.01–2.60)
HDL 40mg/dL 2.23 (1.98–2.48) 0.42
<40mg/dL 2.03 (1.62–2.43)
HgbA1C 5.9% 2.12 (1.83–2.42) 0.29
<5.9% 2.36 (2.02–2.66)
Obesity 24.2kg/m2 1.98 (1.64–2.32) 0.07
<24.2kg/m2 2.39 (2.12–2.67)
IMT 1.0mm 2.30 (2.02–2.58) 0.56
<1.0mm 2.24 (1.80–2.68)
Smoke Smoking 2.32 (1.96–2.68) 0.58
None 2.20 (1.93–2.47)
Gender Male 2.26 (1.97–2.54) 0.84
Female 2.22 (1.93–2.51)
CHD: coronary heart disease.
TCHO: total cholesterol; HDL: high-density lipoprotein; HgbA1C: hemo-
globin A1C; IMT: intimal media thickness.
CI: conﬁdence interval.
PTX3 is expressed in response to proinﬂammatory signals,
including bacteria, IL-1 (but not IL-6), and TNF-alpha
produced by primarily endothelial cells, neutrophils, and
macrophages. As a result, inﬂammation diseases, espe-
cially disorders of the immune system such as rheumatoid
arthritis [31], progressive systemic sclerosis [32], Chug-
Straus syndrome, Wegener’s granulomatosis, and micro-
scopic polyangiitis [33], as well as systemic inﬂammatory
response syndrome (SIRS) [29, 34], result in increased
expression of plasma PTX3. Chronic kidney disease is also
known to increase the level of plasma PTX3 [35, 36].
Therefore, it was also of interest to determine the PTX3
expression patterns in inﬂammatory bowel diseases such as
Crohn’s disease and ulcerative colitis. As IL-6 was found
to have increased expression in active Crohn’s disease, but
not in ulcerative colitis, it is not surprising that plasma
PTX3 levels were increased in patients with only ulcerative
colitis (because IL-1, but not IL-6, causes induction of PTX3
expression). PTX3 may therefore also be a good diagnostic
marker for deterioration in patients with inﬂammatory
bowel disease [37, 38].
5. Conclusion
Advances in genomics and proteomics technologies have led
to the discovery of many novel biomarkers that provide
valuable information, which can be used in disease screening
anddiagnosis,determiningprognoses,andtherapeuticmon-
itoring. One potentially useful biomarker for cardiovascular
disease is PTX3, and many studies have recently examinedInternational Journal of Vascular Medicine 5
this protein in clinical situations. Although PTX3 is in the
same protein family as CRP, it is expressed predominantly in
atherosclerotic lesions. Interestingly, the expression of PTX3
in endothelial cells has been shown in vitro to be suppressed
to a greater extent by pitavastatin than other genes. We
have therefore recently determined the normal physiological
concentration of PTX3. As PTX3 has promise as a biomarker
for cardiovascular disease, we have recently determined
the normal physiological concentration of this protein.
In addition, kits capable of detecting PTX3 are available,
including a highly sensitive kit recently developed by our
group,facilitatingtheuseofPTX3asabiomarker.Additional
clinical study will be necessary to further elucidate the role of
this protein in cardiovascular disease.
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